

Press Release

adivo receives EU grant to accelerate development of novel therapies for inflammatory bowel disease in companion animals

adivo's IBD program is one of two proprietary assets progressing towards first-in-animal studies within the next 12 months

Martinsried/ Munich, Germany, October 17, 2022 – adivo GmbH, a leader in discovering species-specific therapeutic antibodies for pets, today announced that the company will benefit from an approved European Innovation Council (EIC) Accelerator grant to support one of its pipeline programs. The grant has a total volume of EUR 2.5 million and will help accelerate the development of adivo's proprietary therapeutic antibody program addressing the growing need for novel therapeutic options for dogs suffering from inflammatory bowel disease (IBD).

"IBD is affecting a growing number of dogs and their owners worldwide. By transferring a therapeutic principle and target biology that is well validated in humans in a species-specific manner, we aim to provide a best-in-class therapeutic solution for IBD in dogs," commented Dr. Markus Waldhuber, Co-Founder and Chief Development Officer of adivo. "adivo is entering a transformative chapter in its development as two programs are approaching the initiation of first-in-animal studies. The grant funding by the EIC Accelerator program adds to our growing financial muscle and will support adivo in competing for an industry-leading position in the companion antibody therapeutics market."

adivo has established CEASAR, the first fully canine phage display platform in the veterinary medicines market for selecting therapeutic candidates against a broad range of diseases. More recently, the company expanded its technology basis to cover a second companion animal species with significant medical needs and launched FELIX, the first fully synthetic source of therapeutic antibodies on the market to date for cats. The adivo technology platforms allows de-novo identification of species-specific antibodies panels to select drug candidates with optimal functionality, developability and low risk of immunogenicity. Powered by more than two decades of combined therapeutic antibody discovery expertise gained in human medicine, the adivo leadership team is ideally positioned to bring forth developable candidates with best-in-class drug properties and molecular profiles tailored to the targeted species.

About adivo

adivo is forging a new era for companion animal health. Our proprietary phage display antibody libraries deliver species-specific drugs for a growing market need. We apply our extensive drug discovery and protein engineering know-how to address cancer, chronic inflammatory diseases and other serious conditions in pets. Together with our partners, we create the best possible therapeutics for our beloved furry friends. For further information, please visit: www.adivo.vet.

Contact

adivo

Dr. Kathrin Ladetzki-Baehs

Phone +49 89 58 8088 471

E-mail: info@adivo.vet

For media

Mario Brkulj

Valency Communications

Phone: +49 160 9352 9951

E-mail: mbrkulj@valencycomms.eu